ENTITY

Ergomed Plc (ERGO LN)

17
Analysis
Health CareUnited Kingdom
Ergomed plc provides clinical research, and drug development and safety services in the United Kingdom and rest of Europe, the Middle East, Africa, North America, Asia, and Australia. The company offers clinical development, trial management services, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, neurology, and immunology, as well as the development of orphan drugs. The company?s clinical development services include study management, site management, study physician support, safety services, regulatory and quality management, clinical data management and biostatistics, and medical writing. It also provides late phase services, such as strategy and study design, medical training, regulatory consultancy, management of ISTs, full study management, publication management, site management, pharmacovigilance, tailored data capture solutions, REMS and RMPs, and medical information services; and co-development services for pharma and biotech companies. In addition, the company is involved in the studies of ultra-rare diseases, including infantile hypophsophatemia, paroxyzmal nocturnal haemoglobinuria, and primary hyperoxaluria; and the provision of the specialized site management model that allows smooth interaction of the sites and patient organizations, and advocacy groups. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed Plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.
more
bullishErgomed Plc
11 Aug 2021 19:50Issuer-paid

Ergomed - Momentum continues with EBITDA upgrades

Ergomed’s H121 trading update highlights that operational momentum continues to be strong following its stellar performance in FY20. The order book...

Share
bullishErgomed Plc
11 Jun 2021 20:09Issuer-paid

Ergomed - FY21e EBITDA ‘materially ahead’ of consensus

Yesterday, Ergomed held its annual general meeting (AGM) and provided a high-level year to date trading update (four months to end-April 2021). The...

Share
bullishErgomed Plc
01 Jun 2021 18:10Issuer-paid

Ergomed - What’s next after stellar 2020 performance?

Although most of 2020 was challenging for the contract research outsourcing (CRO) sector, for Ergomed it was a transformative growth period due to...

Share
bullishErgomed Plc
22 Sep 2020 19:51Issuer-paid

Ergomed - Adj EBITDA upgrade despite industry challenges

H120 adjusted EBITDA of £9.1m was the main positive surprise for us in Ergomed’s full interim report released today. We have increased our adjusted...

Share
bullishErgomed Plc
23 Jul 2020 16:52Issuer-paid

Ergomed - Diversified services offering proves resilient

According to Ergomed’s H120 trading update, the business successfully navigated the COVID-19 pandemic in H120. Underlying revenues in the...

Share
x